RMD - ResMed Inc.

NYSE - NYSE Delayed Price. Currency in USD
85.29
+1.36 (+1.62%)
At close: 4:03PM EST
Stock chart is not supported by your current browser
Previous Close83.93
Open84.51
Bid0.00 x 0
Ask0.00 x 0
Day's Range84.37 - 85.58
52 Week Range61.22 - 87.81
Volume1,367,193
Avg. Volume608,112
Market Cap12.103B
Beta0.78
PE Ratio (TTM)34.67
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.40 (1.67%)
Ex-Dividend Date2017-11-08
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters5 days ago

    NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

    New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents. Fisher & Paykel said it was seeking a range of legal remedies from the lawsuit, including banning the manufacture and sale of such Resmed products in Australia. Fisher & Paykel and California-based Resmed are engaged in patent disputes in several countries over medical devices used to treat respiratory conditions.

  • Resmed Clears Technical Benchmark, Hitting 80-Plus RS Rating
    Investor's Business Daily11 days ago

    Resmed Clears Technical Benchmark, Hitting 80-Plus RS Rating

    Resmed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

  • See what the IHS Markit Score report has to say about ResMed Inc.
    Markit12 days ago

    See what the IHS Markit Score report has to say about ResMed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • ResMed (RMD) Rides on Innovation Amid Reimbursement Woes
    Zacks15 days ago

    ResMed (RMD) Rides on Innovation Amid Reimbursement Woes

    ResMed (RMD) achieves strong global revenue growth for the past few quarters on the back of sales of sleep devices, respiratory care devices, mask systems and software solutions.

  • Why Is ResMed (RMD) Up 8.4% Since the Last Earnings Report?
    Zacks18 days ago

    Why Is ResMed (RMD) Up 8.4% Since the Last Earnings Report?

    ResMed (RMD) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Capital Cube19 days ago

    ETFs with exposure to ResMed, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ResMed, Inc. Here are 5 ETFs with the largest exposure to RMD-US. Comparing the performance and risk of ResMed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about ResMed Inc.
    Markit26 days ago

    See what the IHS Markit Score report has to say about ResMed Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on October 31. Index (PMI) data, output in the Healthcare sector is rising.

  • 3 Top Medical Device Stocks to Buy Now
    Motley Fool28 days ago

    3 Top Medical Device Stocks to Buy Now

    Looking to put money to work in this under-the-radar sector? Here are three top stocks to consider.

  • Capital Cubelast month

    ETFs with exposure to ResMed, Inc. : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ResMed, Inc. Here are 5 ETFs with the largest exposure to RMD-US. Comparing the performance and risk of ResMed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Reuterslast month

    Fisher & Paykel says UK court rules rival Resmed's patent is invalid

    New Zealand's Fisher & Paykel Healthcare (FPH.NZ) said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's (RMD.N) patent was invalid. Fisher & Paykel filed the case against California-based Resmed in Britain's High Court in 2016, and has similar legal proceedings underway in Germany, after Resmed had said the New Zealand company's masks violated Resmed patents. "This result confirms that UK patients can continue to purchase and enjoy the benefits of our high-performance masks," Fisher & Paykel said in a statement in which it announced the UK court ruling.

  • Reuterslast month

    Fisher & Paykel says UK court rules rival Resmed's patent is invalid

    New Zealand's Fisher & Paykel Healthcare said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's patent was invalid. Fisher & Paykel filed the case against California-based Resmed in Britain's High Court in 2016, and has similar legal proceedings underway in Germany, after Resmed had said the New Zealand company's masks violated Resmed patents.

  • Read This Before Buying ResMed Inc (RMD) For Its Upcoming $0.35 Dividend
    Simply Wall St.last month

    Read This Before Buying ResMed Inc (RMD) For Its Upcoming $0.35 Dividend

    Important news for shareholders and potential investors in ResMed Inc (NYSE:RMD): The dividend payment of $0.35 per share will be distributed into shareholder on 14 December 2017, and the stockRead More...

  • Capital Cubelast month

    ETFs with exposure to ResMed, Inc. : November 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ResMed, Inc. Here are 5 ETFs with the largest exposure to RMD-US. Comparing the performance and risk of ResMed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about ResMed Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about ResMed Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on October 31. Index (PMI) data, output in the Healthcare sector is rising.

  • ResMed, Inc. :RMD-US: Earnings Analysis: Q1, 2018 By the Numbers : November 1, 2017
    Capital Cubelast month

    ResMed, Inc. :RMD-US: Earnings Analysis: Q1, 2018 By the Numbers : November 1, 2017

    Categories: Yahoo FinanceGet free summary analysis ResMed, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ResMed, Inc. – Thermo Fisher Scientific Inc. (TMO-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 523.66 million, Net Earnings of USD 86.13 million. ... Read more (Read more...)

  • Resmed Meets 80-Plus Relative Strength Rating Benchmark
    Investor's Business Daily2 months ago

    Resmed Meets 80-Plus Relative Strength Rating Benchmark

    Resmed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 68 to 82.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RMD earnings conference call or presentation 26-Oct-17 8:30pm GMT

    Q1 2018 Resmed Inc Earnings Call

  • Here's Why ResMed Inc. Stock Spiked Today
    Motley Fool2 months ago

    Here's Why ResMed Inc. Stock Spiked Today

    Another strong earnings report suggests this company's growth story isn't over yet.

  • ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines
    Zacks2 months ago

    ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines

    ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.

  • Associated Press2 months ago

    ResMed beats 1Q profit forecasts

    On a per-share basis, the San Diego-based company said it had net income of 60 cents. Earnings, adjusted for amortization costs, came to 66 cents per share. The results topped Wall Street expectations. ...

  • See what the IHS Markit Score report has to say about ResMed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about ResMed Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on October 4. Index (PMI) data, output in the Healthcare sector is rising.

  • MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More
    Zacks2 months ago

    MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More

    Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.

  • Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?
    Zacks2 months ago

    Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?

    ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.

  • Capital Cube2 months ago

    ETFs with exposure to ResMed, Inc. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ResMed, Inc. Here are 5 ETFs with the largest exposure to RMD-US. Comparing the performance and risk of ResMed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)